ScholarIQanswers from OpenAlex
Humanitas Gavazzeni
InstitutionResearch output, impact & collaborations
Humanitas Gavazzeni is a institution indexed in ScholarIQ from OpenAlex.
What is known about Humanitas Gavazzeni?
ScholarIQrecord summary
Humanitas Gavazzeni is a research organisation in Bergamo, IT. OpenAlex records 1,781 works and 75,322 citations for it. 413 researchers list it as their most recent affiliation.
How many works does Humanitas Gavazzeni have?
ScholarIQindexed works
Humanitas Gavazzeni has 1,781 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Humanitas Gavazzeni have?
ScholarIQcitation count
Humanitas Gavazzeni has 75,322 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Humanitas Gavazzeni?
ScholarIQresearcher count
Humanitas Gavazzeni has 413 researchers in the ScholarIQ index.
What is the average h-index at Humanitas Gavazzeni?
ScholarIQavg h-index
Humanitas Gavazzeni has an average h-index of 44 in OpenAlex.
What is the ROR of Humanitas Gavazzeni?
ScholarIQror
The ROR for Humanitas Gavazzeni is on the source record.
What is the OpenAlex record for Humanitas Gavazzeni?
ScholarIQopenalex
The OpenAlex for Humanitas Gavazzeni is on the source record.
Who are the most-cited researchers behind Humanitas Gavazzeni?
ScholarIQtop researchers by citations
What are the most-cited papers on Humanitas Gavazzeni?
ScholarIQmost cited works
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinò, Myung‐Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin Solomon, Fiona Blackhall, Yi‐Long Wu, Michael Thomas, Kenneth J. O’Byrne, Denis Moro‐Sibilot, D. Ross Camidge, Tony Mok, Vera Hirsh, Gregory J. Riely, Shrividya Iyer, Vanessa Tassell, Anna Polli, Keith D. Wilner, Pasi A. Jänne
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Juergen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Yvonne Lau, Meredith A. Goldwasser, Anthony Boral, Jeffrey A. Engelman
Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis
Fabio Conforti, Laura Pala, Vincenzo Bagnardi, Tommaso De Pas, Marco Martinetti, Giuseppe Viale, Richard D. Gelber, Aron Goldhirsch
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa, Tommaso De Pas, M. Zieliński, Moon Soo Kim, Jacek Jassem, Masahiro Yoshimura, Jubrail Dahabreh, Haruhiku Nakayama, Libor Havel, Haruhiko Kondo, Tetsuya Mitsudomi, Paul Zarogoulidis, Oleg Gladkov, Katalin Udud, Hirohito Tada, Hans Hoffman, Anders Bugge, Paul Taylor, Emilio Esteban Gonzalez, Mei Lin Liao, Jianxing He, Jean-Louis Pujol, Jamila Louahed, Muriel Debois, Vincent Brichard, C. Debruyne, Patrick Therasse, Nasser K. Altorki
Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial
Dong‐Wan Kim, Ranee Mehra, Daniel S.W. Tan, Enriqueta Felip, Laura Q.M. Chow, D. Ross Camidge, Johan Vansteenkiste, Sunil Sharma, Tommaso De Pas, Gregory J. Riely, Benjamin Solomon, Jürgen Wolf, Michael Thomas, Martin Schüler, Geoffrey Liu, Armando Santoro, Santosh Sutradhar, Siyu Li, Tomasz Szczudlo, A. Yovine, Alice T. Shaw
How much of the research on Humanitas Gavazzeni is open access?
ScholarIQopen access share
73%OPEN ACCESS